Van den Bossche, Dorien De Smet, Dieter Debrabandere, Johan Vanpoucke, Hilde
Published in
Clinical Chemistry and Laboratory Medicine (CCLM)
Background Infliximab (IFX) is an effective therapy in patients with inflammatory bowel disease. Serum IFX trough concentrations correlate well with clinical, biological and endoscopic outcomes. Therefore, therapeutic drug monitoring (TDM) of infliximab is useful for dose optimization and prevention of secondary treatment failure. In the present st...
Skochko, SM Jain, S Sun, X Sivilay, N Kanegaye, JT Pancheri, J Shimizu, C Sheets, R Tremoulet, AH Burns, JC
...
© 2018 Elsevier Inc. Objectives: To describe the epidemiology, response to therapy, and outcomes of Kawasaki disease in a multiethnic community with a large Hispanic and Asian population. Study design: We analyzed prospectively collected data from 788 unselected patients with Kawasaki disease diagnosed and treated at a single medical center over a ...
Segal, J Rottoli, M Felwick, R Worley, G McLaughlin, S Vallicelli, C Bassett, P Faiz, O Hart, A Clark, S
...
Aim: Prepouch ileitis (PPI) is inflammation of the ileum proximal to an ileoanal pouch, usually associated with pouchitis. The treatment of PPI as a specific entity has been poorly studied, but it is generally treated concurrently with pouchitis. This to our knowledge is the largest study to explore the efficacy of biologics for the specific treatm...
Metcalfe, Clive Dougall, Thomas Bird, Chris Rigsby, Peter Behr-Gross, Marie-Emmanuelle Wadhwa, Meenu Study, Participants Of The
Published in
mAbs
Due to the increase in the number of infliximab products, the need for global harmonization of the bioactivity of this monoclonal antibody was recognized by the World Health Organization (WHO). In response, the National Institute for Biological Standards and Control (NIBSC) developed the first international standard (IS) for infliximab, which targe...
Goyal, Gaurav Shah, Mithun V Call, Timothy G Litzow, Mark R Wolanskyj-Spinner, Alexandra P Koster, Matthew J Tobin, W Oliver Vassallo, Robert Ryu, Jay H Hook, Christopher C
...
Published in
British journal of haematology
Kizaki, Kazuha Yamashita, Fumiharu Hayashi, Tomoya Funakoshi, Noboru
Published in
International journal of rheumatic diseases
This study was designed to investigate which biological agent, infliximab or tocilizumab, would more intensively keep suppressing oxidative stress among well-controlled patients as C-reactive protein (CRP) levels normalized in rheumatoid arthritis (RA). In addition, it was intended to clarify indicative factors of oxidative stress among well-contro...
Ge, Victor Banakh, Iouri Tiruvoipati, Ravindranath Haji, Kavi
Published in
Clinical case reports
Given the current understanding of bleomycin-induced pneumonitis (BIP), the use of tumor necrosis factor alpha (TNF-α) inhibitors such as infliximab for late-stage disease appears to be of limited benefit. Further research regarding prevention and management of advanced BIP is required.
Barclay, Murray Lindsay Karim, Shwan Helms, Esther Theodora Johanna Keating, Paula Elizabeth Hock, Barry Stamp, Lisa Katrina Schultz, Michael
Published in
Internal medicine journal
We aimed to correlate IBD disease activity in New Zealand patients with trough concentrations of infliximab and adalimumab using a locally developed enzyme-linked immunosorbent assay (ELISA), and anti-drug antibodies (ADA) using competitive-binding ELISA and homogeneous mobility shift assay (HMSA), to establish threshold concentrations. Patients wi...
lopetuso, loris riccardo mocci, giammarco marzo, manuela d’aversa, francesca rapaccini, gian lodovico guidi, luisa armuzzi, alessandro gasbarrini, antonio papa, alfredo
agents with and without pre-existent hepatic diseases. In addition, the available evidence on their potential benefits in the treatment of specific hepatic diseases is discussed.
Yu, X.-J. Shen, Y.-F. Dong, J. Li, T. Wang, C. Zhang, Y.-J. Wang, L.-F. Meng, Y.-C. Yang, Y. Wang, H.-J.
...
Published in
Molecular Biology
Previously, we have reported the crystal structures of Fab fragment of Infliximab in complex with TNFα. The structurally identified epitope on TNFα revealed the mechanism of TNFα inhibition by partially overlapping with the TNFα-receptor interface and the possibility to optimize the binding affinity. In this study, we launched a screen of a phage d...
